Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $67.00 at Robert W. Baird

Key Points

• Robert W. Baird has raised its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $50.00 to $67.00, indicating a potential upside of 110.69% from its previous close.
• Despite the positive outlook from analysts, Dianthus reported a loss of ($0.88) earnings per share last quarter, falling short of estimates, with total revenue significantly below expectations at $0.19 million.
• Seven research analysts have rated Dianthus Therapeutics as a Buy, with a consensus price target of $56.83, highlighting strong institutional interest in the company.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) had its price target boosted by investment analysts at Robert W. Baird from $50.00 to $67.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Robert W. Baird's price target suggests a potential upside of 110.69% from the company's previous close.

DNTH has been the topic of several other reports. William Blair assumed coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a research report on Thursday, August 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $56.83.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $31.80 on Tuesday. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $32.80. The stock has a market cap of $1.02 billion, a PE ratio of -9.78 and a beta of 1.46. The firm's 50-day simple moving average is $21.54 and its 200 day simple moving average is $20.09.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The firm had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. As a group, analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP boosted its holdings in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after buying an additional 1,499,931 shares during the period. RA Capital Management L.P. boosted its holdings in Dianthus Therapeutics by 53.6% in the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock worth $52,003,000 after buying an additional 1,000,333 shares during the period. Octagon Capital Advisors LP boosted its holdings in Dianthus Therapeutics by 11.0% in the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock worth $42,478,000 after buying an additional 231,500 shares during the period. Alliancebernstein L.P. boosted its holdings in Dianthus Therapeutics by 14.5% in the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock worth $21,887,000 after buying an additional 149,200 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in Dianthus Therapeutics by 14.4% in the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company's stock worth $23,607,000 after buying an additional 136,314 shares during the period. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.